Triple-Targeted Oncolytic Adenoviruses Featuring the Cox2 Promoter, E1A Transcomplementation, and Serotype Chimerism for Enhanced Selectivity for Ovarian Cancer Cells
Open Access
- 1 August 2006
- journal article
- research article
- Published by Elsevier in Molecular Therapy
- Vol. 14 (2) , 164-174
- https://doi.org/10.1016/j.ymthe.2006.01.010
Abstract
No abstract availableKeywords
This publication has 29 references indexed in Scilit:
- Cancer Statistics, 2005CA: A Cancer Journal for Clinicians, 2005
- Enhanced therapeutic efficacy for ovarian cancer with a serotype 3 receptor-targeted oncolytic adenovirusMolecular Therapy, 2003
- Gene Transfer to Ovarian Cancer Versus Normal Tissues with Fiber-Modified AdenovirusesMolecular Therapy, 2002
- Selectively replicating adenoviruses targeting deregulated E2F activity are potent, systemic antitumor agentsCancer Cell, 2002
- Adenoviruses in OncologyBioDrugs, 2002
- Human Papillomavirus E6E7-Mediated Adenovirus Cell Killing: Selectivity of Mutant Adenovirus Replication in Organotypic Cultures of Human KeratinocytesJournal of Virology, 2001
- An adenovirus E1A mutant that demonstrates potent and selective systemic anti-tumoral efficacyNature Medicine, 2000
- A mutant oncolytic adenovirus targeting the Rb pathway produces anti-glioma effect in vivoOncogene, 2000
- Cancer Cell CyclesScience, 1996
- An Adenovirus Mutant That Replicates Selectively in p53- Deficient Human Tumor CellsScience, 1996